Vertex Pharmaceuticals is trading 4.02% lower at $486.60 on October 13, 2026; no clear company-specific announcement explaining the decline surfaced, while biotech-sector weakness provides context.

  • XBI was down 2.01% during the regular session, but sector weakness does not fully explain Vertex’s larger move.
  • BofA trimmed its price target to $667 from $672 and maintained a Buy rating; the modest change does not establish a direct cause.
  • Broader major-index moves were comparatively small.